|Bid||141.37 x 800|
|Ask||142.00 x 1000|
|Day's range||133.34 - 143.99|
|52-week range||31.71 - 189.26|
|Beta (5Y monthly)||1.38|
|PE ratio (TTM)||N/A|
|Earnings date||05 May 2021 - 10 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||174.25|
A proposal currently before the World Trade Organization would waive patent rights on COVID-19 vaccines and treatments in an effort to help low-income nations. Several top Democrats appear to support the move, although the Biden administration has yet to state a position publicly. Despite the push, the president may be hesitant to override patents for pharmaceuticals.
Suzanne Judd, Epidemiologist at the University of Alabama at Birmingham School of Public Health, joined Yahoo Finance to discuss the latest on covid-19.
Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.